potassium acid phosphate (Rx)

Brand and Other Names:KPhos Original, NeutraPhos
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 500mg

Elevated Urinary pH

1-2 tabs (500-1000mg) dissolved in 6-8 oz of water; take PO four times daily with meals and at bedtime

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and potassium acid phosphate

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (9)

              • amiloride

                amiloride and potassium acid phosphate both increase serum potassium. Avoid or Use Alternate Drug.

              • drospirenone

                drospirenone and potassium acid phosphate both increase serum potassium. Avoid or Use Alternate Drug.

              • eplerenone

                potassium acid phosphate, eplerenone. Mechanism: pharmacodynamic synergism. Contraindicated. Hyperkalemia.

              • erdafitinib

                potassium acid phosphate, erdafitinib. Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid coadministration during initial dosing adjustment period (ie, first 21 days). Increases in serum phosphate levels are a pharmacodynamic effect of FGFR inhibition. Serum phosphate binders may obscure decisions regarding initial dosage increase.

              • potassium chloride

                potassium acid phosphate and potassium chloride both increase serum potassium. Avoid or Use Alternate Drug.

              • potassium citrate

                potassium acid phosphate and potassium citrate both increase serum potassium. Avoid or Use Alternate Drug.

              • potassium phosphates, IV

                potassium acid phosphate and potassium phosphates, IV both increase serum potassium. Avoid or Use Alternate Drug.

              • spironolactone

                spironolactone and potassium acid phosphate both increase serum potassium. Avoid or Use Alternate Drug.

              • triamterene

                triamterene and potassium acid phosphate both increase serum potassium. Avoid or Use Alternate Drug.

              Monitor Closely (107)

              • acebutolol

                acebutolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • aceclofenac

                aceclofenac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • acemetacin

                acemetacin and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • albuterol

                potassium acid phosphate increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • arformoterol

                potassium acid phosphate increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • aspirin

                aspirin and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • aspirin rectal

                aspirin rectal and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • aspirin/citric acid/sodium bicarbonate

                aspirin/citric acid/sodium bicarbonate and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • atenolol

                atenolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • benazepril

                benazepril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.

                potassium acid phosphate and benazepril both increase serum potassium. Use Caution/Monitor. Potassium salts may increase the hyperkalemic effects of ACE inhibitors; the effect may be the result of aldosterone suppression in patients receiving ACE inhibitors

              • bendroflumethiazide

                potassium acid phosphate increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • betaxolol

                betaxolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • bisoprolol

                bisoprolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • bumetanide

                potassium acid phosphate increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • canagliflozin

                potassium acid phosphate and canagliflozin both increase serum potassium. Modify Therapy/Monitor Closely.

              • candesartan

                candesartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.

              • captopril

                captopril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.

              • carbenoxolone

                potassium acid phosphate increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • carvedilol

                carvedilol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • celecoxib

                celecoxib and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • celiprolol

                celiprolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • chlorothiazide

                potassium acid phosphate increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • chlorthalidone

                potassium acid phosphate increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • choline magnesium trisalicylate

                choline magnesium trisalicylate and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • cyclopenthiazide

                potassium acid phosphate increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • diclofenac

                diclofenac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • diflunisal

                diflunisal and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • digoxin

                potassium acid phosphate and digoxin both increase serum potassium. Modify Therapy/Monitor Closely.

              • disopyramide

                potassium acid phosphate increases effects of disopyramide by pharmacodynamic synergism. Use Caution/Monitor. Additive cardiovascular depression.

              • dobutamine

                potassium acid phosphate increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • dopexamine

                potassium acid phosphate increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • enalapril

                enalapril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.

              • ephedrine

                potassium acid phosphate increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • epinephrine

                potassium acid phosphate increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • epinephrine racemic

                potassium acid phosphate increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • eprosartan

                eprosartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.

              • esmolol

                esmolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • ethacrynic acid

                potassium acid phosphate increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • etodolac

                etodolac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • fenoprofen

                fenoprofen and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • finerenone

                potassium acid phosphate and finerenone both increase serum potassium. Modify Therapy/Monitor Closely. Finerenone dose adjustment based on current serum potassium concentration. Monitor serum potassium and adjust finerenone dose as described in the prescribing information as necessary.

              • flurbiprofen

                flurbiprofen and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • formoterol

                potassium acid phosphate increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • fosinopril

                fosinopril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.

              • furosemide

                potassium acid phosphate increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • gentamicin

                potassium acid phosphate increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • hydrochlorothiazide

                potassium acid phosphate increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • ibuprofen

                ibuprofen and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • ibuprofen IV

                ibuprofen IV and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • imidapril

                imidapril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.

              • indapamide

                potassium acid phosphate increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • indomethacin

                indomethacin and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • irbesartan

                irbesartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.

              • isoproterenol

                potassium acid phosphate increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • ketoprofen

                ketoprofen and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • ketorolac

                ketorolac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • ketorolac intranasal

                ketorolac intranasal and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • labetalol

                labetalol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • levalbuterol

                potassium acid phosphate increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • lisinopril

                lisinopril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.

              • lornoxicam

                lornoxicam and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • losartan

                losartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.

              • meclofenamate

                meclofenamate and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • mefenamic acid

                mefenamic acid and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • meloxicam

                meloxicam and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • metaproterenol

                potassium acid phosphate increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • methyclothiazide

                potassium acid phosphate increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely. .

              • metolazone

                potassium acid phosphate increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • metoprolol

                metoprolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • moexipril

                moexipril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.

              • nabumetone

                nabumetone and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • nadolol

                nadolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • naproxen

                naproxen and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • nebivolol

                nebivolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • noni juice

                potassium acid phosphate and noni juice both increase serum potassium. Use Caution/Monitor.

              • norepinephrine

                potassium acid phosphate increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • olmesartan

                olmesartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.

              • oxaprozin

                oxaprozin and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • parecoxib

                parecoxib and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • penbutolol

                penbutolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • perindopril

                perindopril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.

              • pindolol

                pindolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • pirbuterol

                potassium acid phosphate increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • piroxicam

                piroxicam and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • potassium citrate/citric acid

                potassium acid phosphate and potassium citrate/citric acid both increase serum potassium. Use Caution/Monitor.

              • propranolol

                propranolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • quinapril

                quinapril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.

              • ramipril

                ramipril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.

              • sacubitril/valsartan

                sacubitril/valsartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.

              • salicylates (non-asa)

                salicylates (non-asa) and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • salmeterol

                potassium acid phosphate increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • salsalate

                salsalate and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • sotalol

                sotalol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • succinylcholine

                potassium acid phosphate and succinylcholine both increase serum potassium. Modify Therapy/Monitor Closely.

              • sulfasalazine

                sulfasalazine and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • sulindac

                sulindac and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • telmisartan

                telmisartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.

              • terbutaline

                potassium acid phosphate increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • timolol

                timolol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • tolfenamic acid

                tolfenamic acid and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • tolmetin

                tolmetin and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

              • tolvaptan

                potassium acid phosphate and tolvaptan both increase serum potassium. Modify Therapy/Monitor Closely.

              • torsemide

                potassium acid phosphate increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.

              • trandolapril

                trandolapril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.

              • trimethoprim

                trimethoprim and potassium acid phosphate both increase serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.

              • valsartan

                valsartan and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.

              • voclosporin

                voclosporin and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.

              Minor (29)

              • acarbose

                potassium acid phosphate increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • amphotericin B deoxycholate

                amphotericin B deoxycholate decreases levels of potassium acid phosphate by increasing renal clearance. Minor/Significance Unknown.

              • bisacodyl

                bisacodyl decreases levels of potassium acid phosphate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              • bisacodyl rectal

                bisacodyl rectal decreases levels of potassium acid phosphate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              • cadexomer iodine

                cadexomer iodine increases levels of potassium acid phosphate by decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.

              • chlorpropamide

                potassium acid phosphate increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • glimepiride

                potassium acid phosphate increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • glipizide

                potassium acid phosphate increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • glyburide

                potassium acid phosphate increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • insulin aspart

                potassium acid phosphate increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • insulin detemir

                potassium acid phosphate increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • insulin glargine

                potassium acid phosphate increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • insulin glulisine

                potassium acid phosphate increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • insulin lispro

                potassium acid phosphate increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • insulin NPH

                potassium acid phosphate increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • insulin regular human

                potassium acid phosphate increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • iodinated glycerol

                iodinated glycerol increases levels of potassium acid phosphate by decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.

              • iodine

                iodine increases levels of potassium acid phosphate by decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.

              • metformin

                potassium acid phosphate increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • miglitol

                potassium acid phosphate increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • nateglinide

                potassium acid phosphate increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • pioglitazone

                potassium acid phosphate increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • repaglinide

                potassium acid phosphate increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • rosiglitazone

                potassium acid phosphate increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • saxagliptin

                potassium acid phosphate increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • sitagliptin

                potassium acid phosphate increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • tolazamide

                potassium acid phosphate increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • tolbutamide

                potassium acid phosphate increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              • vildagliptin

                potassium acid phosphate increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

              Previous
              Next:

              Adverse Effects

              Frequency Not Defined

              Diarrhea

              Nausea/vomiting

              Stomach pain

              Flatulence

              Bradycardia

              Hyperkalemia

              Local tissue necrosis with extravasation

              Weakness

              Dyspnea

              Hypocalcemia

              Tetany

              Phosphate intoxication

              Hypotension

              Arrhythmia

              Previous
              Next:

              Warnings

              Contraindications

              Hyperphosphatemia, severe renal impairment, hyperkalemia, infected phophate stones

              Cautions

              May cause hyperkalemia; use caution in patients who require regulation of serum potassium concentrations

              Patients may experience mild laxative effects within first few days of therapy

              Use caution in patients with severe adrenal insufficiency, cardiac disease, myotonia congenita, pancreatitis, parathyroid disease, renal calculi, renal impairment, tissue breakdowns (burns), or rickets

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy Category: C

              Lactation: Use with caution

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Intracellular cation essential in physiological processes including transmission of nerve impulses, glucose utilization, muscle contractions, and enzyme activity

              Acidifies urine

              Pharmacokinetics

              Distribution: Enters cells from extracellular fluid via active transport

              Absorption: Well absorbed from upper GI tract

              Excretion: Urine (primarily); skin and feces (small amount)

              Previous
              Next:

              Images

              No images available for this drug.
              Previous
              Next:

              Patient Handout

              A Patient Handout is not currently available for this monograph.
              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.